

Biologic Treatment Adherence and Persistence in Patients with Palmoplantar Pustulosis: A Real-World, Claims-Based Study – Supplementary Material

Steven R. Feldman,¹ Ran Gao,^{2*} Rhonda L. Bohn,³ Stephani Gray,³ Anouk Déruaz-luyet,⁴ Jashin J. Wu⁵

¹Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA; ²Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA; ³Bohn Epidemiology, Boston, MA, USA; ⁴Boehringer Ingelheim International GmbH, Ingelheim, Germany; ⁵Department of Dermatology, University of Miami Miller School of Medicine, Miami, FL, USA

*Ran Gao is now an employee of Gilead Sciences.

Correspondence: Dr. Jashin Wu, Department of Dermatology, University of Miami Miller School of Medicine, 1600 NW 10th Ave #1140, Miami, FL 33136, USA; Phone: 305-243-6735; Fax: 305-243-6191; E-mail: jashinwu@gmail.com

TABLE S1 Biologic class and individual treatments

Biologic class	Individual treatment
TNF- α inhibitors	Certolizumab pegol
	Etanercept
	Adalimumab
	Infliximab
	Golimumab
IL inhibitors	Secukinumab
	Ustekinumab
	Brodalumab
	Ixekizumab
	Guselkumab
	Tildrakizumab
	Risankizumab
T-cell inhibitors	Abatacept

Abbreviations: IL, interleukin; TNF- α , tumor necrosis factor alpha.